A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors.
Perez K, Kulke MH, Zheng H, Allen J, Clark J, Enzinger AC, Enzinger PC, Johnson BE, McCleary NJ, Parikh A, Patel A, Rubinson D, Yurgelun MB, Ramsey K, Johnson E, Graham C, Chan JA.
Perez K, et al. Among authors: johnson e.
Oncologist. 2025 Jan 17;30(1):oyae364. doi: 10.1093/oncolo/oyae364.
Oncologist. 2025.
PMID: 39834129
Clinical Trial.